Aardvark Therapeutics Inc. Common Stock
AARD | NASDAQ
$5.57
+$0.19 (+3.53%)
At close: Sep 21, 2026, 4:00 PM ET
$5.56
-$0.01 (-0.18%)
After-hours:
Sep 21, 2026, 7:54 PM ET
Fiscal Quarter Period Ending | Q2 2026 Jun 29, 2026 | Q1 2026 Mar 30, 2026 | Q4 2025 Dec 30, 2025 | Q3 2025 Sep 29, 2025 | Q2 2025 Jun 29, 2025 | Q1 2025 Mar 30, 2025 | Q4 2024 Dec 30, 2024 | Q3 2024 Sep 29, 2024 | Q2 2024 Jun 29, 2024 | Q1 2024 Mar 30, 2024 | Q4 2023 Dec 30, 2023 | Q3 2023 Sep 29, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -15.08M | -22.46M | -18.7M | -17.7M | -15.85M | -10.47M | -9.45M | -5.09M | -6.07M | -2.17M | -2.23M | -1.72M |
Interest Income | 695K | 889K | 1.13M | 1.35M | 1.49M | 1.18M | 717K | 1M | 594K | 103K | 118K | 135K |
Pretax Income | -14.39M | -21.59M | -17.6M | -16.32M | -14.37M | -9.31M | -8.78M | -4.18M | -5.45M | -2.18M | -2.04M | -2.11M |
Net Income | -14.39M | -21.59M | -17.6M | -16.32M | -14.37M | -9.31M | -8.78M | -4.18M | -5.45M | -2.18M | -2.04M | -2.11M |
Selling & General & Admin | 4.63M | 5.9M | 4.41M | 3.97M | 2.7M | 2.72M | 1.39M | 1.03M | 2.03M | 861K | 525K | 538K |
Research & Development | 10.46M | 16.57M | 14.3M | 13.74M | 13.15M | 7.76M | 8.06M | 4.07M | 4.03M | 1.21M | 1.54M | 964K |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 14K | 103K | 171K | 217K |
Operating Expenses | 15.08M | 22.46M | 18.7M | 17.7M | 15.85M | 10.47M | 9.45M | 5.09M | 6.07M | 2.17M | 2.23M | 1.72M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 15.08M | 22.46M | 18.7M | 17.7M | 15.85M | 10.47M | 9.45M | 5.09M | 6.07M | 2.17M | 2.23M | 1.72M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 21.85M | 21.82M | 21.82M | 21.75M | 21.69M | 21.69M | 21.7M | 21.38M | 21.38M | 21.38M | 21.38M | 21.38M |
Shares Outstanding (Diluted) | 21.85M | 21.82M | 21.82M | 21.75M | 21.69M | 21.69M | 21.7M | 21.38M | 21.38M | 21.38M | 21.38M | 21.38M |
EPS (Basic) | -0.66 | -0.99 | -0.81 | -0.75 | -0.66 | -0.43 | -0.40 | -0.20 | -0.25 | -0.10 | -0.10 | -0.10 |
EPS (Diluted) | -0.66 | -0.99 | -0.81 | -0.75 | -0.66 | -0.43 | -0.40 | -0.20 | -0.25 | -0.10 | -0.10 | -0.10 |
EBITDA | -14.39M | -21.58M | -17.59M | -16.31M | -14.36M | -9.31M | -8.78M | -4.17M | -6.01M | -2.18M | -2.04M | -1.48M |
EBIT | -14.39M | -21.59M | -17.6M | -16.32M | -14.37M | -9.31M | -8.78M | -4.18M | -6.06M | -2.18M | -2.06M | -1.5M |
Depreciation & Amortization | n/a | 11K | 10K | 10K | 11K | 5K | n/a | 8K | 48K | 2K | 25K | 26K |
Add to Watchlist
Select watchlists to add or remove AARD